Bone Therapeutics long-serving CEO steps down, leaving interim successor in charge

Belgium

Enrico Bastianelli is stepping down as CEO of Bone Therapeutics after 10 years at the job. The exit, which Bone Therapeutics attributed to personal reasons, leaves former Eli Lilly ($LLY) and Lundbeck commercial director Thomas Lienard in charge of the company on an interim basis.

Gosselies, Belgium-based Bone Therapeutics signaled it had news of note shortly after trading began on the Euronext exchange in Brussels on Tuesday morning. When the Belgian Financial Services and Markets Authority’s request to suspend trading lifted 5 hours later--and less than one hour after news of Bastianelli’s departure broke--shares of the microcap biotech traded down 6%.

The news amounted to a brief statement that Bastianelli is leaving Bone Therapeutics after 10 years at the company. Bastianelli led Bone Therapeutics from its first days as a Université libre de Bruxelles spinoff in 2006 through to its €37 million ($41 million) IPO last year, but is now leaving as the firm enters a 12-month period littered with clinical readouts for its bone-forming cell therapy.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Responsibility for guiding Bone Therapeutics toward those readouts will now fall on Lienard, who joined the company as chief business officer late last year. Lienard arrived at Bone Therapeutics on the back of a four-year stint as managing director of Lundbeck’s commercial operations in Belgium and Luxembourg, before which he spent 7 years rising through the ranks of Lilly’s sales teams.

With Lienard joining ex-Pfizer ($PFE) medical director Guy Heynen among the people to land at Bone Therapeutics in recent years, Chairman Michel Helbig de Balzac thinks the business is equipped to cope with the loss of its long-serving leader.

“Over the past year, we have built a strong management team to take the Company through the next phase of its growth, including the eventual commercialisation of our first products, and will continue to progress our growth strategy and advanced clinical programmes under the interim leadership of Thomas Lienard,” Helbig said in a statement.

Helbig gave no indication of how long the search for a successor will take. Bone Therapeutics is closing in on multiple major milestones, including the delivery of top-line data from three mid-phase trials of its allogeneic cell therapy Allob in assorted skeletal conditions.

Related Article:
Bone Therapeutics posts interim PhIIa data, building case for bone-forming cell therapy

Suggested Articles

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical failures.